Shire plc (ADR)

Another Strong Year for Shire plc With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34

Baird Maintains an 'Outperform' on Shire plc (SHPGY); Like Clockwork, Another Positive Update & Outlook

Shire price target raised to $124 from $114 at RW Baird

Shire 4Q profit soars 55 percent behind drug sales

Shire says Genzyme claim on Fabrazyme dosing "misleading"

Shire's Profits and Sales Beat Views, Forecasts Strong 2012

Shire says not planing European sales force expansion for Vyvanse

Shire says sees 2012 gross margins "marginally lower"

Shire Q4 Profit Rises, EPS Tops View; Sees Earnings Growth In 2012 - Update

Shire reports Q4 adjusted EPS $1.51 vs. consensus $1.37

Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34

Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD

Shire Pharma Surges On USDA's Decision

Shire and Sangamo Cut a Deal - Analyst Blog

Shire and Sangamo Cut a Deal - Analyst Blog

Shire and Sangamo Cut a Deal

Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD

Shire plc (SHPGY) Gets FDA Approval for Adult ADHD Medication Vyvanse

Shire's Vyvanse gets FDA approval as maintenence treatment in adults with ADHD

Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD

Resource sector suitors move apart on the FTSE 100

Shire and Sangamo BioSciences collaborate on therapeutics development

The FDA Pediatric Advisory Committee to hold a meeting

FDA approves Genzyme Framingham plant

Shire Donates $1.4 Million To Philadelphia Boys and Girls Clubs

Shire upgraded to Neutral from Underperform at Exane BNP Paribas

Prasco Labs launches authorized generic of Shire's Carbatrol

Prasco® Launches Authorized Generic of Shire's Carbatrol®

Shire acquires U.S. rights to Resolor

Shire gets U.S. rights to Resolor from Janssen

Shire Acquires US Rights to Resolor(R) (prucalopride)

Shire (SHPGY) Grabs U.S. Rights to Resolor

Investor Advisory Service's "Top Stock Picks for 2012" Presented Live at RetailInvestorConferences.com on January 12th

AstraZeneca results blunder forces reissue

ICON chosen by Shire plcs Specialty Pharma's unit as global strategic partner

Shire downgraded to Hold from Buy at Societe Generale

ICON Selected by Shire plc’s Specialty Pharmaceuticals division as Global Strategic Partner for Clinical Research and Central Laboratory Services

ICON Selected by Shire plc’s Specialty Pharmaceuticals division as Global Strategic Partner for Clinical Research and Central Laboratory Services

Shire's Venvanse® (Lisdexamfetamine Dimesylate) Marketing Application Accepted For Review In Europe

Shire's Venvanse marketing application accepted for review in Europe